Lipocine Stock Forum

$Lipocine (LPCN.US)$
Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea
Lipocine Inc. (NASDAQ: LPCN) has entered into a license, development and supply agreement with SPC Korea for exclusive marketing rights of TLANDO® in South Korea. The agreement includes an upfront payment, potential regulatory and sales milestone payments, royalties on net commercial sales, and a supply price arrangement. SPC Korea will be responsible for obtaining...

$Lipocine (LPCN.US)$ Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
● Quantitative Electroencephalogram (qEEG) in healthy subjects administered single doses of oral brexanolone, a neuroactive steroid (NAS), confirmed GABAA modulation
● Rapid and durable CNS target engagement confirms effective oral delivery of bioidentical brexanolone
● Promising results support continued development of oral brexanolone for the treatment of neuropsychiatric disorders

SALT LAKE CI...

$Lipocine (LPCN.US)$
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries
Lipocine Inc. (NASDAQ: LPCN) has announced an exclusive supply and distribution agreement with Pharmalink to commercialize TLANDO®, its oral testosterone replacement therapy, in the Gulf Cooperation Council (GCC) countries. The agreement covers Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman.
Under the term...

$Lipocine (LPCN.US)$ Reuters just
Lipocine Announces Supply and Distribution Agreement With Pharmalink to Commercialize Tlando® in the Gulf Cooperation Council (GCC) Countries

$Lipocine (LPCN.US)$
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with at least one weight-related comorbidity
SALT LAKE CITY, Sept. 5, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that a poster featuring Phase 2 da...

$ROCHE HOLDING AG (RHHBY.US)$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$ $Structure Therapeutics (GPCR.US)$ $Viking Therapeutics (VKTX.US)$ $Lipocine (LPCN.US)$

$United Therapeutics (UTHR.US)$  Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$  Phase 3
$Liquidia (LQDA.US)$  Phase 3
$United Therapeutics (UTHR.US)$  Phase 3
$MorphoSys (MOR.US)$  Phase 3
$Immunocore (IMCR.US)$  Phase 3
$Crinetics (CRNX.US)$  Phase 3
$UroGen Pharma Ltd (URGN.US)$  Phase 3
$AstraZeneca (AZN.US)$  Phase 3
$AstraZeneca (AZN.US)$  Phase 3
$AstraZeneca (AZN.US)$  Phase 3
$AstraZeneca (AZN.US)$  Phase 3
$Capricor Therapeutics (CAPR.US)$  Phase 3
$Annexon (ANNX.US)$  Phase 3
$Lipocine (LPCN.US)$  Phase 3...

$Lipocine (LPCN.US)$
NEWS
LIPOCINE ANNOUNCES LATE BREAKING ORAL PRESENTATION OF DATA FROM THE PHASE 2 STUDY OF LPCN 1148 AT EASL CONGRESS 2024
Lipocine Inc. announced that data from the Phase 2 study of LPCN 1148 will be presented at the EASL Congress 2024 in Italy. The study shows improvement in sarcopenia and hepatic encephalopathy in cirrhosis patients.
Positive
Data from the Phase 2 study of LPCN 1148 selected for late breaking oral presentation at EASL Congress 2024.
Intervention with oral L...

$Lipocine (LPCN.US)$ Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, Lpcn 1154.  Lipocine Inc: Topline Results Anticipated Late in 2Q 2024

$Travere Therapeutic (TVTX.US)$  Phase 3
$CG Oncology (CGON.US)$  Phase 3
$United Therapeutics (UTHR.US)$  Phase 3
$United Therapeutics (UTHR.US)$  Phase 3
$BioCardia (BCDA.US)$  Phase 3
$Insmed (INSM.US)$  Phase 3
$GlycoMimetics (GLYC.US)$  Phase 3
$Annexon (ANNX.US)$  Phase 3
$Lipocine (LPCN.US)$  Phase 3
$FibroGen (FGEN.US)$  Phase 3
$UroGen Pharma Ltd (URGN.US)$  Phase 3
$Lyra Therapeutics (LYRA.US)$  Phase 3
$Citius Pharmaceuticals (CTXR.US)$  Phase 3
$Jaguar Health (JAGX.US)$  Phas...